As of 2024-12-11, the Relative Valuation of Avidity Biosciences Inc (RNA) is (66.06) USD. This relative valuation is based on P/E multiples. With the latest stock price at 36.85 USD, the upside of Avidity Biosciences Inc based on Relative Valuation is -279.3%.
The range of the Relative Valuation is (67.28) - (74.62) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 28.6x - 45.5x | 35.3x |
| Forward P/E multiples | 20.1x - 31.7x | 20.9x |
| Fair Price | (67.28) - (74.62) | (66.06) |
| Upside | -282.6% - -302.5% | -279.3% |
| Date | P/E |
| 2024-11-25 | -19.16 |
| 2024-11-22 | -18.40 |
| 2024-11-21 | -18.10 |
| 2024-11-20 | -18.57 |
| 2024-11-19 | -18.40 |
| 2024-11-18 | -17.59 |
| 2024-11-15 | -17.94 |
| 2024-11-14 | -21.26 |
| 2024-11-13 | -22.33 |
| 2024-11-12 | -19.88 |
| 2024-11-11 | -20.04 |
| 2024-11-08 | -19.87 |
| 2024-11-07 | -20.21 |
| 2024-11-06 | -20.09 |
| 2024-11-05 | -19.18 |
| 2024-11-04 | -19.06 |
| 2024-11-01 | -17.81 |
| 2024-10-31 | -17.98 |
| 2024-10-30 | -18.38 |
| 2024-10-29 | -18.96 |
| 2024-10-28 | -19.45 |
| 2024-10-25 | -19.19 |
| 2024-10-24 | -19.21 |
| 2024-10-23 | -19.31 |
| 2024-10-22 | -20.15 |
| 2024-10-21 | -19.87 |
| 2024-10-18 | -21.46 |
| 2024-10-17 | -20.64 |
| 2024-10-16 | -20.82 |
| 2024-10-15 | -19.86 |
| 2024-10-14 | -19.87 |
| 2024-10-11 | -19.82 |
| 2024-10-10 | -18.81 |
| 2024-10-09 | -19.46 |
| 2024-10-08 | -19.71 |
| 2024-10-07 | -18.69 |
| 2024-10-04 | -20.12 |
| 2024-10-03 | -20.01 |
| 2024-10-02 | -20.04 |
| 2024-10-01 | -20.63 |
| 2024-09-30 | -19.54 |
| 2024-09-27 | -18.01 |
| 2024-09-26 | -17.94 |
| 2024-09-25 | -19.55 |
| 2024-09-24 | -18.72 |
| 2024-09-23 | -18.50 |
| 2024-09-20 | -18.92 |
| 2024-09-19 | -19.42 |
| 2024-09-18 | -18.98 |
| 2024-09-17 | -17.95 |